REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity's technology suite.
This collaboration comes at the heels of another recent pilot, shortly after Biotricity established strategic partnerships with leading GPOs, which wield immense purchasing power, totaling $264 billion. The collective GPO partnerships Biotricity has established provide a staggering 90% of hospitals nationwide with access to its technology. Leveraging this in conjunction with its innovative TaaS model, Biotricity ensures that advanced medical care is accessible to all, dismantling barriers to healthcare accessibility.
"Securing this pilot study not only validates the transformative potential of our solutions but also signifies a significant step towards redefining disease profiling, patient management, and preventative care methodologies," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "Our strategic partnerships with GPOs [Group Purchasing Organizations] were key to launching this major cardiac monitoring pilot program and underscores our commitment to advancing the healthcare industry."
With its sights set on a $35 billion market opportunity, Biotricity stands as a beacon of innovation and is primed to transform the future of healthcare. Investors are encouraged to explore Biotricity's robust revenue trajectory and comprehensive suite of medical diagnostic and consumer healthcare technologies at www.biotricity.com/investors.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Investor Relations Contacts
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BTCY@redchip.com
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
